Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and three have given a strong buy rating to the company.

Several equities research analysts have commented on the stock. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th.

Zealand Pharma A/S Price Performance

Shares of Zealand Pharma A/S stock opened at $48.89 on Friday. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $46.26 and its two-hundred day moving average price is $61.32. Zealand Pharma A/S has a 52 week low of $35.93 and a 52 week high of $83.12. The stock has a market cap of $3.50 billion, a PE ratio of 3.63 and a beta of 0.87.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.50%. The firm had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. As a group, sell-side analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.